TradeFlare's AI research teams analysed APLS on 5 market nights between May 13, 2026 and May 19, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| May 19, 2026 | BUY | $41.03 | — / — | not yet | not yet | Continued strong revenue growth driven by successful product launches. |
| May 18, 2026 | BUY | $41.03 | — / — | not yet | not yet | Continued strong revenue growth driven by successful product launches. |
| May 15, 2026 | HOLD | $41.03 | — / — | not yet | not yet | The acquisition by Biogen at $41 per share is the primary driver. |
| May 14, 2026 | BUY | $41.03 | — / — | not yet | not yet | Pending acquisition by Biogen. |
| May 13, 2026 | HOLD | $41.06 | — / — | not yet | not yet | Biogen's tender offer at $41 per share provides a clear, near-term price target. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.